AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for E3 ubiquitin-protein ligase MARCHF9

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q86YJ5

UPID:

MARH9_HUMAN

Alternative names:

Membrane-associated RING finger protein 9; Membrane-associated RING-CH protein IX; RING finger protein 179; RING-type E3 ubiquitin transferase MARCHF9

Alternative UPACC:

Q86YJ5; B2R9U9; Q86VN5; Q96GG2

Background:

E3 ubiquitin-protein ligase MARCHF9, also known as Membrane-associated RING finger protein 9, plays a crucial role in the ubiquitination process. It mediates the ubiquitination of key proteins such as MHC-I, CD4, and ICAM1, facilitating their endocytosis and degradation in lysosomes. This process is vital for cellular homeostasis and the regulation of immune responses.

Therapeutic significance:

Understanding the role of E3 ubiquitin-protein ligase MARCHF9 could open doors to potential therapeutic strategies. Its involvement in protein ubiquitination and immune regulation presents a unique opportunity for the development of novel treatments targeting autoimmune diseases and cancer.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.